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1. Introduction  
Pharmaceutical nanoparticles were first described in 1970s, and the term “nanotechnology” 
is now commonly used to refer to the fabrication of new materials with nanoscale 
dimensions between 1 and 100 nm (Thrall 2004). Several types of nanometer scale systems 
such as nanoparticles, nanospheres, nanotubes, nanogels and molecular conjugates are 
being investigated (Lemieux et al. 2000;Liu et al. 2007;Ravi et al. 2004). The field of 
nanomedicine aims to use the properties and physical characteristics of nanomaterials 
which have been extensively investigated as novel intravascular or cellular probes for both 
diagnostic (imaging) and therapeutic purposes (drug/gene delivery). The sub-micron size of 
nanoparticle delivery systems confers distinct advantages as compared to large sized 
systems including targeted delivery, higher and deeper tissue penetrability, greater cellular 
uptake and greater ability to cross the blood-brain barrier (Kreuter et al. 1995;Vinogradov et 
al. 2002;Vogt et al. 2006). Therapeutic transgene(s) encoded by plasmid or chemically 
modified DNA can be dissolved, entrapped, chemically conjugated, encapsulated or 
adsorbed to the surface of nanoparticles. There are, broadly, two main types of nanosized 
particles with different inner structures: A. Nanoparticle/Nanosphere: Matrix composed of 
entangled oligomer or polymer units; and B. Nanocapsule: Reservoir consisting of a 
hydrophobic core surrounded by a polymer wall. Lipids can also be used to generate 
liposomes or micelles (discussed in detail later). These nanodevices can confer protection to 
the DNA against a variety of degradative and destabilizing factors, and enhance delivery 
efficiency to the cells while minimizing the toxic effects.  
Nanoparticles are expected to play a critical role in the innovation and development of 
future cancer treatment modalities. Recent research has developed functional nanoparticles 
that are covalently linked to biological molecules such as peptides, proteins, nucleic acids, or 
small-molecule ligands (Alivisatos 2004;Chan et al. 2002;Michalet et al. 2005). Medical 
applications have also appeared, such as the use of superparamagnetic iron oxide 
nanoparticles as a contrast agent in the detection of lymph node prostate cancer 
(Harisinghani et al. 2003) and the use of polymeric nanoparticles for targeted gene delivery 
to tumor vasculatures (Hood et al. 2002). Target-specific drug/gene delivery and early 
diagnosis is currently a high priority R&D area, and one in which nanomedicine will 
inevitably make critical contributions. Current modalities of diagnosis and treatment of 
various diseases, especially cancer, have major limitations such as poor sensitivity or 
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specificity and high drug toxicities respectively. The success of nanoparticle delivery 
systems will ultimately depend on the ability to efficiently deliver the gene of interest and 
express a therapeutic gene(s) in tumor cells in a targeted manner in order to mitigate 
toxicity. This chapter examines current existing nanoparticle-based gene therapy approaches 
to cancer treatment, and assesses their therapeutic utility. 
2. Nanobased cancer treatment strategies  
Most neoplasm’s are derived from multiple mutations and rarely can be controlled through 
the targeting of a single mutation. The efficacy of gene therapy in tumor treatment will 
undoubtedly rely upon the simultaneous targeting of multiple cellular processes or the 
ability to invoke various antitumor responses. Current clinical trials in cancer exploit a 
variety of different treatment approaches. Tumor suppressor modalities compensate for a 
genetic mutation via gene transfer or replacement of an altered tumor suppressor gene (e.g. 
p53, BRCA1). Molecular chemotherapy, involves the transfer of a suicide gene (e.g. Herpes 
Simplex Virus-thymidine kinase [HSV-tk], CD::upp) targeted to specific tissues by 
extracellular tumor/tissue targeting strategies, and/or via tissue-specific expression. The 
delivered gene then makes the cell susceptible to a prodrug (e.g. gancyclovir, 5-FC) making 
tumor-specific expression critical. Tumor immunotherapy involves the gene transfer of 
cytokines (e.g. IL-2, IL-12) that impart antitumor immunomodulatory properties. Oncofactor 
inhibition strategies such as growth factor inhibition and oncogene inhibition (e.g. erb-B2 
silencing) aim to prevent tumor progression by inhibiting key growth factors. Anti-
angiogenesis therapy seeks to destroy the vasculature supplying the tumor in the hopes of 
starving it of essential nutrients to diminish or prevent its progression. Multi Drug 
Resistance associated genes strategies, involve knocking down gene associated with or 
conferring MDR, such as PRP-4 and survivin to improve chemosensitivity. We will examine 
in detail each of these strategies.  
2.1 Tumor suppressor gene therapy 
As a critical player in cancer onset, p53 has come to the forefront of oncological research and 
is now recognized to be the single most frequently inactivated gene in human cancers (Ning 
et al. 2011;Olivier et al. 2002;Olivier et al. 2010). The p53 gene enforces a variety of anticancer 
functions by encouraging cells to arrest or die in the face of DNA damage, hypoxia, 
oxidative stress, excessive mitogenic stimuli or denuded telomers. In addition, the protein 
influences several biological functions such as involvement in cell cycle regulation, 
programmed cell death, senescence, differentiation and development, transcription, DNA 
replication, DNA repair and maintenance of genomic stability. Thus, it’s not surprising that 
p53 is regarded as the “Guardian of the Genome” in preventing human neoplasia (Lane 1992). 
P53 protein has emerged as a key tumor suppressor protein in cellular stress response 
pathways. The p53 gene, mapped to chromosome 17p13.1, consists of 11 exons spanning 
over 20 kb of DNA encoding a 393 amino acid and 53 kDa nuclear protein. Its structure 
consists of an acidic N-terminus with a transactivation domain, a hydrophobic central DNA-
binding core and a basic C-terminus with regulatory and oligomerization domains (Hainaut 
and Vahakangas 1997). Although greater than 90% of the isolated mutations in this gene 
have been localized to the DNA binding site of p53, coded by exons 5 to 8; some mutations 
have also been reported outside the evolutionary conserved regions (Hainaut and Hollstein 
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2000). The p53 gene product is a sequence-specific nuclear transcription factor that binds to 
defined consensus sites within DNA as a tetramer and affects the transcription of its target 
genes. These target genes are involved in critical cell processes such as: 
1. Growth arrest: P21, Gadd45 and 14-3-3σ. 
2. DNA repair: P53R2.  
3. Apoptosis: Bax, Bcl-xL, Fas, FasL, DR5/Killer, Apaf-1, Puma and Noxa.  
The loss of p53 function is of relevance to a broad array of cancer types, including 15–50% of 
breast cancer cases, 25–70% of metastatic prostate cancers, 25–75% of lung cancers, 33–100% 
of head and neck cancers and 60-80% advanced ovarian cancers (Ruley, 1996). Furthermore, 
the null mutation of the gene imparts strongly unfavorable prognosis when associated 
within human ovarian, lung, colon and breast cancer cases. P53 also represses genes 
involved in tumor angiogenesis, and recent evidence suggests that tumor cells possessing a 
wild-type p53 allele are more sensitive to chemotherapeutic agents and radiation than p53 
null mutants (Lowe et al. 1994). The pleiotropic abnormalities imparted by deficient p53 in a 
significant fraction of human cancers make it one of the primary candidates for cancer gene 
therapy, whereby the effective expression or replacement of p53 may re-establish cell 
growth control, restore appropriate responses to DNA-damaging agents (e.g. chemotherapy 
and radiotherapy) and preclude tumor angiogenesis. In human neoplasia’s that express the 
wild-type protein, aberrations of p53 regulators, such as MDM2, account for p53 inhibition. 
For this reason, improved understanding of the p53 pathway should lead to better diagnosis 
and treatment of cancer in the future. 
The p53 gene therapeutic, Gendicine, is currently approved in China and its US counterpart, 
Advexin, has shown activity in number of clinical trials. In more conventional approaches a 
range of small drug like molecules targeting the p53 mediated system have been developed 
and several are now in clinical trials. Of critical importance has been the development of 
small-molecule inhibitors of the p53–Mdm2 protein interaction such as the Nutlins (Vassilev 
2004), which have shown activity against human xenografts in preclinical models. 
Therefore, designing small-molecule inhibitors of the p53-MDM2 protein-protein interaction 
is a promising strategy for the treatment of cancers retaining wild-type p53 (Lauria et al. 
2010). Advanced structural approaches have provided compelling support for the idea that 
some p53 mutants can be targets for small molecules that would cause them to regain wild-
type function (Joerger et al. 2006). Many adenoviral vectors with cancer specific conditional 
replication properties have been preclinically evaluated to date. Most promising among 
these are: i) the Ad dl1520 that possesses a deletion of the 55-kd E1B gene limiting growth to 
only p53-deficient tumor cells. This strategy has shown preclinical efficacy against p53-
deficient nude mouse-human ovarian carcinomatosis xenografts (Vasey et al. 2002); and ii) 
the integrin-targeted Ad5-D24RGD and serotype 3 receptor-targeted Ad5/3-D24 that 
possesses a 24 bp deletion in the retinoblastoma binding site of E1A, conferring selective 
replication in cancer cells that are deficient in the Rb/p16 pathway. 
2.2 Molecular chemotherapy 
Suicide gene therapy/molecular chemotherapy is a new experimental form of cancer 
chemotherapy that is currently being evaluated in human trials (Bhaumik 2011; Onion et al. 
2009;Xu et al. 2009). This approach involves intra-tumoral delivery of genes encoding 
enzymes that convert nontoxic prodrugs into toxic anti-metabolites. Two suicide genes that 
are being evaluated in the clinic are the Escherichia coli CD (codA cytosine deaminase) and 
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HSV-1 tk (thymidine kinase) genes, which confer sensitivity to 5-FC  (5-flourocytosine) and 
GCV , respectively. The rationale behind the suicide gene therapy approach is that after 
"targeted" transfer of these genes to the tumor, only tumor and neighboring cells will be 
rendered sensitive to their cytotoxic action. A variety of tumor models have demonstrated 
that both the CD/5-FC (by inhibiting thymidylate synthase) and HSV-1 tk/GCV prodrug 
systems (by inhibiting DNA chain elongation) can enhance the efficacy of radiation therapy, 
resulting in significantly better tumor control and/or cure (Rogulski et al., 1997). Suicide 
gene therapy is a particularly attractive approach to the treatment of cancer as it is 
essentially a tumor-targeted chemotherapy. As such, the systemic toxicity commonly 
associated with, and a major limitation of, conventional chemotherapy is avoided. Using a 
pair of adenoviral vectors that express a CD/HSV-1 tk fusion gene without or with the wt 
human p53 gene, it has been found that co-expression of p53 did not enhance the cytotoxicity 
of CD/5-FC or HSV-1 tk/GCV suicide gene therapies using the SK-OV-3 and Hep3B tumor 
models in vitro or in vivo (Xie et al., 1999). This notion is consistent with the fact that CD/5-
FC and HSV-1 tk/GCV suicide gene therapies have demonstrated effectiveness against a 
variety of tumors that lack functional p53 (e.g., SK-OV-3, Hep3B, 9L, WiDr, U251, DU145, 
PC-3, C33A, and many others). Azatian et al. (Azatian et al. 2009) investigated the 
effectiveness of HSV-tk activation as gene therapy for gastroesophageal junction and gastric 
adenocarcinomas using a stress-inducible Grp78 promoter. The gastric adenocarcinoma cell 
line MKN-74/tk cells were completely killed when cultured with 1 µg/ml GCV for 10 days. 
Cell viability was also significantly lower under glucose starvation conditions when HSV-tk 
expression was regulated by the Grp78 promoter . Furthermore, non-viral approaches are 
being investigated for use in combination with suicide gene therapy for treatment of various 
carcinomas. Using transferrin lipoplexes, prepared from cationic liposomes and cholesterol, 
significant tumor reduction was achieved upon intratumoral delivery of HSV-tk or CD 
genes, followed by intraperitoneal injection of GCV or 5-FC, respectively (Neves et al. 2009). 
Enhanced apoptosis, the recruitment of NK cells, CD4 and CD8 T-lymphocytes and an 
increase in the levels of several cytokines/chemokines were observed within the tumors. 
These observations suggest that suicide gene therapy with lipoplexes modifies the tumor 
microenvironment, and leads to the recruitment of immune effector cells that can act as 
adjuvants in reducing the tumor size. 
2.3 Immunomodulatory strategies 
Tumor cells alter antigen presentation on their surface compromising recognition by the 
immune system and immunosurveillance evasion. Tumor immunotherapy strategies aim to 
boost the anti-tumor immune response by stimulating the cell-mediated arm of the immune 
system (Wojtowicz-Praga 1997). Gene therapy approaches to enhance immune responses 
include delivery of cytokines to the tumor, administration of tumor vaccines based on 
tumor-associated antigens (TAAs), upregulation of Major Histocompatibitlity Complexes 
(MHC)(Nabel et al. 1993) or co-stimulatory molecules, and inhibition of immunosuppressive 
molecules. Many cytokines activate the immune system, including interleukins (IL) 2, 4, 7, 
12 and 18, interferon γ (IFN-γ), tumor necrosis factor α (TNF-α), and granulocyte–
macrophage colony-stimulating factor (GM-CSF), which are among the most potent 
inducers of anti-tumor activity in a variety of preclinical studies. More recently, some 
exciting new cytokines have been characterized, such as IL-21, IL-23, IL-27, and their 
immunomodulatory and antitumor effects in vitro and in vivo suggest that they may have 
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considerable promise for future immunotherapy protocols (Weiss et al. 2007). Recent studies 
using animal models have shown that genetically modified tumor cells expressing cytokines 
such as IL-2, IL-4, IL-6, IFN-γ or GM-CSF were capable of inducing an immune response 
against preexisting tumors (Connor et al. 1993). In preclinical models and clinical trials, 
cytokines have been delivered to melanoma lesions by intratumoral injection of naked 
DNA, recombinant viral vectors and transduced tumor cells and fibroblasts (Sun et al. 1998). 
Initial clinical trials evaluating the systemic delivery of IL-2 and TNF-α were complicated by 
significant systemic toxicity (Rosenberg 1999), thereby generating interest in gene transfer 
strategies that limit cytokine production to the tumor milieu. Preclinical studies employing 
TAAs to generate tumor vaccines have been promising, and seem to suggest that 
immunization with recombinant, virus-encoding TAAs can confer suppression of growth in 
pre-established tumors and the production of specific cytotoxic T lymphocyte responses. 
However, conversion to clinical trials has failed to show significant efficacy. 
The cytokine IFN-γ has been shown to up-regulate MHC expression, antigen processing, 
antigen processing and presentation expression in many cell populations, including 
dendritic cells, B cells, macrophages, and endothelial cells, producing more potent antigen 
presenting cells (APCs), as IFN-γ can induce multiple gene expressions that are related to 
MHC processing and presentation. Dendritic cells (DCs) play a vital role in the initiation of 
immune response as professional antigen presenting cells to T cells promoting CD8+ T-cell-
mediated cytotoxic responses. Reported research in animal studies indicates that vaccine 
immunity may represent a promising alternative therapy for cancer patients. However, 
broad clinical utility has yet to be achieved, owing to the low transfection efficiency of DCs 
(Chen et al. 2010b). Different formulations of liposomes have been designed to improve the 
uptake by DCs through different receptor-mediated routes. These formulations include 
liposomes prepared with mannosylated phosphatidylethanolamine (Man-PE), trimethyl 
ammonium propane, and phosphatidylserine targeted to mannose receptor (MR), 
negatively charged surface proteins and phosphatidylserine receptor (PSR) of DCs, 
respectively. Several other immunomodulatory clinical trials are under way with cytokines 
currently comprising 18.3% of immunotherapy clinical trials (http://www.wiley.com/ 
legacy/wileychi/genmed/clinical/). Table 1 provides a list of various types of genes 
currently involved in various gene therapy clinical trials. A number of other monoclonal 
antibodies; namely EC90, Removab, and CNTO-95 which target FOLR1, EpCAM and α-
integrin (CD51), respectively are in Phase I/II studies, and indicate that further clinical 
investigation in this area is warranted  (Bell-McGuinn et al. 2011;Kowalski et al. 2010). 
2.4 Oncofactor inhibition strategies  
2.4.1 Growth factor inhibition  
The epidermal growth factor receptor (EGFR) belongs to the proto-oncogene family, which 
consists of four structurally-related transmembrane receptors (i.e., EGFR, ErbB2, ErbB3, and 
ErbB4) and is a key therapeutic target in the treatment of many types of cancer. The most 
extensively studied growth factors are ErbB1 (Javle et al. 2010) and ErbB2 (Nihira 2003). 
These ErbB/EGF receptors are tyrosine kinases and play important physiologic roles in cell 
proliferation, survival, adhesion, motility, invasion, and angiogenesis. High expression of 
EGF receptor protein is observed in several types of cancer including breast, bladder, colon, 
lung and gastric cancers, making them potential targets for targeted therapies, which 
represent some of the most successful therapeutic approaches to date (Iqbal et al. 2011;Lai et 
al. 2009;Yarom and Jonker 2011).  
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Gene Therapy Clinical Trials 
Number % 
Adhesion molecule 10 0.6 
Antigen 334 20.7 
Antisense 13 0.8 
Cell cycle 8 0.5 
Cell protection/Drug resistance 19 1.1 
Cytokine 317 18.5 
Deficiency 136 7.9 
Growth factor 128 7.5 
Hormone 8 0.5 
Marker 54 3.2 
Oncogene regulator 11 0.6 
Oncolytic virus 37 2.2 
Porins, ion channels, 
transporters 12 0.7 
Receptor 113 6.6 
Replication inhibitor 74 4.3 
Ribozyme 6 0.4 
siRNA 11 0.6 
Suicide 144 8.4 
Transcription factor 28 1.6 
Tumor suppressor 150 8.8 
Viral vaccine 6 0.4 
Others 26 1.5 
Unknown 49 2.9 
Total 1714  
Table 1. List of various types of genes presently involved in various gene therapy clinical 
trials (Source: http://www.wiley.com/legacy/wileychi/genmed/clinical/). 
Gefitinib and Erlotinib are small molecules that exert their function by inhibiting the 
intracellular tyrosine kinase domain of EGFR. Recently, the southwest oncology group 
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study S0413, a phase II trial of lapatinib  was conducted as first-line therapy in patients 
with advanced or metastatic gastric cancer. Median (95% CI) time to treatment failure was 
1.9 (1.6-3.1) months and overall survival (OS) was 4.8 (3.2-7.4) months. Lapatinib is well 
tolerated, with modest single-agent activity in advanced/metastatic gastric cancer 
patients. Potential molecular correlatives such as HER2, interleukin (IL)-8 and genomic 
polymorphisms IL-8, and vascular endothelial growth factor correlated with OS (Iqbal et 
al. 2011). Similarly, in other Phase II studies with single agent Gefitinib or Erlotinib only 
modest activity was observed. Gefitinib cytotoxic combinations are also currently under 
examination (Wagner et al. 2007).  Further, very recently it was observed that direct 
covalent coupling of antibodies to glutaraldehyde activated nanoparticles is an 
appropriate method to achieve cell-type specific drug carrier systems based on polymeric 
nanoparticles that have potential to be applied for targeted chemotherapy in EGFR 
positive cancer (Aggarwal et al. 2011). 
Trastuzumab (trade name Herceptin) is the first anticancer drug generated by Genentech, 
Inc. whose use as a treatment for breast cancer patients is decided based on the status of the 
HER2 gene amplification/HER2 protein over-expression. The development and 
standardization of an HER2 test was a key strategy in clinical development of this drug, 
since appropriate selection of patients with HER2 over-expression was critical for success. 
This also highlights the important and evolving era of personalized and targeted therapies. 
In the clinic, the success of imatinib (Gleevec®, STI571) and trastuzumab, both firsts of their 
kind, spurred further development of new, second-generation drugs that target kinases in 
cancer.  Further, these targeted drugs combined with chemotherapeutic drugs are found 
effective and well tolerated in nanoparticle based drug delivery (e.g. albumin-bound 
paclitaxel combined with carboplatin and trastuzumab or as trastuzumab-dextran iron 
oxide nanoparticles) for the treatment of cancer (Conlin et al. 2010). 
2.4.2 Signal transduction (P13K/AKT/mTOR pathway) inhibition  
Phosphoinositide 3-kinase (PI3K) is a major signaling component downstream of growth 
factor receptor tyrosine kinases (RTKs). PI3K catalyzes the production of the lipid second 
messenger phosphatidylinositol-3,4,5-triphosphate (PIP3) at the cell membrane. PIP3 in 
turn contributes to the recruitment and activation of a wide range of downstream targets, 
including the serine-threonine protein kinase Akt (also known as protein kinase B). The 
PI3K-Akt-mTOR signaling pathway regulates many normal cellular processes including 
cell proliferation, survival, growth, and motility—processes that are critical for 
tumorigenesis. Components of this pathway are frequently abnormal in a variety of 
tumors, making them an attractive target for anti-cancer therapy. In contrast to p53 and 
other tumor-suppressor pathways, the PI3K pathway is activated in cancer, making this 
an optimal target for therapy as it is easier to inhibit activation events than to replace lost 
tumor-suppressor function. Studies have demonstrated that phosphorylative activation 
via the mTOR pathway results in increased G1 cell cycle progression, cell survival, and 
tumor cell proliferation (Campbell et al. 2004;Vega et al. 2006). The mTOR pathway has 
been shown in preclinical studies to play a role in the carcinogenesis of breast, ovary and 
prostate as well as gastrointestinal malignancies. Novel analogs of rapamycin 
(temsirolimus, everolimus, and deforolimus), which have improved pharmaceutical 
properties, have been designed for oncology indications. Clinical trials of these analogs 
have already validated the importance of mTOR inhibition as a novel treatment strategy 
for several malignancies (Gibbons et al. 2009).  
www.intechopen.com
 Non-Viral Gene Therapy 
 
522 
2.4.3 Oncogene inhibition  
Gene therapy has also been employed in a reversed approach, namely by inhibition of 
oncogenes. The use of vectors to express anti-sense (ODN), ribozymes or small interfering 
RNAs (siRNA) to silence a variety of oncogenes has enabled genetic loss-of-function 
studies in tissue culture systems. Gene expression can be disrupted at the transcriptional 
(triplex DNA) or translational (antisense DNA or short inference RNA) level (Braasch et 
al. 2002). In the triplex DNA-based antigene approach, transcription is disrupted by the 
binding of a triplex-forming oligonucleotide at the promoter region of a target gene. In the 
antisense strategy, the oligonucleotide (ON) molecule corresponding to a target gene is 
delivered inside a cell where it binds to its complementary, targeted messenger RNA 
(mRNA), to produce a partially double-stranded ON/mRNA complex. Extensive work in 
this area has already led to one antisense ON product approved for local therapy of 
cytomegalovirus retinitis (Vitravene) and nearly twenty others in late-stage clinical trials 
(Cheung et al. 2010). 
Silencing of specific mRNA using double stranded RNA oligonucleotides represents one of 
the newest technologies for suppressing a specific gene product. Small interfering RNA 
(siRNA) are 21 nucleotides long, double stranded RNA fragments that are identical in 
sequence to the target mRNA. Silencing of specific gene targets, such as cancer-associated 
mutations in oncogenes and their amplification in tumors therefore represents promising 
therapeutic approach in treating cancer, and strategies focusing on classic oncogenes (such 
as bcl-2, ras and HER-2/neu) have been extensively explored in esophageal, breast, ovarian 
and other carcinomas. Other candidate targets may include genes associated with cell 
proliferation, metastasis, angiogenesis, and drug resistance. Very recently, Liang et al., 
(2011) showed that DNA vector-based Stat3-specific RNA interference (si-Stat3) blocks Stat3 
signalling which was delivered by hydroxyapatite nanoparticles and suppresses mouse 
prostate tumor growth in vivo. In this study, the Stat3 downstream genes Bcl-2, VEGF and 
cyclin D1 were also strongly downregulated in the tumor tissues that also displayed 
significant increases in Bax expression and Caspase3 activity (Liang et al. 2011). While the 
application of antisense technology to the treatment of human cancer is conceptually 
straightforward, selection of appropriate gene targets is an important parameter in the 
potential success of siRNA cancer therapies (Ashihara 2010), and in practice there are many 
complicated, mechanistically based questions that must be considered. Importantly, folding 
of target RNAs or their association with specific proteins in the cell often prevents the ON 
molecules from binding to their targets. In addition, silencing of such genes must not affect 
the functions of normal cells.  
2.5 Anti-angiogenic therapy  
The ability of solid tumors to grow locally, and subsequently disseminate to distant organs, 
is dependent upon the formation of new blood vessels (Azad et al. 2008) and involves 
angiogenic factors such as vascular endothelial growth factor (VEGF). VEGF plays an 
important role in the proliferation of cancer cells, angiogenesis and vascular permeability in 
peritoneal dissemination. BevacizumAb, the only United States Food and Drug 
Administration (FDA)-approved anti-VEGF agent, is a monoclonal antibody that inhibits 
the binding of VEGF to VEGF receptors. CBO-P11, a cyclo-peptide, has proven to 
specifically bind to receptors of VEGF and may be used as targeting ligand for tumor 
angiogenesis. Deshayes et al., (2011) investigated the conjugation of CBO-P11 on the surface 
of poly(vinylidene fluoride) nanoparticles using the copper(I)-catalyzed Huisgen 1,3-dipolar 
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cycloaddition known as a “click” reaction. Nanoparticles were found to be spherical, dense, 
monodisperse and stable. No cytotoxicity was observed after four days of incubation 
demonstrating the biocompatibility of nanoparticles. Fluorescence highlighted the specific 
interaction of these functionalized nanoparticles for VEGF receptors, suggesting that the 
targeting peptide bioactivity was retained (Deshayes et al. 2011). Therapies based on mAb 
targeting and blocking of vascular endothelial growth factor, such as that conferred by the 
monoclonal bevacizumAb, have clearly demonstrated remarkable antitumor efficacy, 
although the mechanism of action here is not well understood. Combined treatment of 
bevacizumAb with Sorafenib (a small molecular inhibitor of several tyrosine protein kinases 
such as VEGFR and PDGFR) resulted in partial response or disease stabilization for ≥ 4 
months (median, 6 months; range, 4 to 22+ months) in 22 (59%) of 37 assessable patients 
with advanced solid tumors .  
Matrix metalloproteases (MMPs) are a family of more than 20 zinc and calcium dependent 
enzymes that degrade all major basement membrane and extracellular matrix components. 
These enzymes also promote tumor invasion and metastasis, regulating host defense 
mechanisms and normal cell function. They are well adapted to serve as signaling conduits 
in the tumor-stromal microenvironment given their crucial roles in the complex processes of 
tissue invasion, blood vessel homeostasis, and metastasis. Specifically, MMP-1, MMP-2 and 
MMP-9 mRNA expression in multivariate analyses has been correlated with a well-
characterized clinical significance in solid tumors but have no such role in effusions, 
suggesting the clinical role of MMP is limited to solid lesions. MMP inhibitors (MMPIs) are 
expected to be useful for the treatment of diseases such as cancer, osteoarthritis, and 
rheumatoid arthritis. A vast number of MMPIs have been developed in recent years. With 
the failure of these inhibitors in clinical trials, more efforts have been directed to the design 
of specific inhibitors with different Zn-binding groups (Tu et al. 2008). 
2.6 Multidrug resistance inhibition/gene transfer strategies  
Cancer cells counter the influx of a chemotherapeutic by draining the drug from cells, 
deactivating the protein that transports the drug across cell walls, restoring DNA breaks, or 
developing some other mechanism to deactivate the drug. Multidrug resistance continues to 
be a major problem in the management of cancer and knockdown of drug resistance 
associated genes such as MDR1 (ABCB1), survivin, and pre-mRNA processing factor-4 
(PRP-4) has been attempted in cancer cell lines.  PRP-4 belongs to the serine/threonine 
protein kinase family, plays a role in pre-mRNA splicing and cell mitosis whereas survivin, 
a member of the inhibitor of apoptosis family of proteins, is implicated in both apoptosis 
inhibition and cell cycle control. Recently, Chen et al., (2010) developed two nanoparticle 
formulations, cationic liposome-polycation-DNA (Whitmore et al. 1999) and anionic 
liposome-polycation-DNA (LPD-II), for systemic co-delivery of doxorubicin (Dox) and a 
therapeutic small interfering RNA (siRNA) to multiple drug resistance (Hesdorffer et al. 
1998) tumors. In this study, they have provided four strategies to overcome drug resistance. 
First, the investigators formed the LPD nanoparticles with a guanidinium-containing 
cationic lipid, i.e. N,N-distearyl-N-methyl-N-2-(N'-arginyl) aminoethyl ammonium chloride, 
which can induce reactive oxygen species, down-regulate MDR transporter expression, and 
increase Dox uptake. Second, to block angiogenesis and increase drug penetration, the 
authors have further formulated LPD nanoparticles to co-deliver vascular endothelial 
growth factor siRNA and Dox. An enhanced Dox uptake and a therapeutic effect were 
observed when combined with vascular endothelial growth factor siRNA in the 
www.intechopen.com
 Non-Viral Gene Therapy 
 
524 
nanoparticles. Third, to avoid P-glycoprotein-mediated drug efflux, they further designed 
another delivery vehicle, LPD-II, which showed much higher entrapment efficiency of Dox 
than LPD. Finally, the authors delivered a therapeutic siRNA to inhibit MDR transporter. 
Three daily intravenous injections of therapeutic siRNA and Dox (1.2 mg/kg) co-formulated 
in either LPD or LPD-II nanoparticles showed a significant improvement in tumor growth 
inhibition (Chen et al. 2010a). Numerous other similar studies highlights a potential clinical 
use for these multifunctional nanoparticles with an effective delivery property and a 
function to overcome drug resistance in cancer. 
3. Delivery systems 
Over the past 20 years, a variety of techniques have been developed for encapsulating both 
conventional drugs (such as anticancer drugs and antibiotics) and new genetic drugs 
(plasmid DNA containing therapeutic genes, antisense oligonucleotides and small 
interfering RNA) within nanoparticles. Nanoparticle delivery systems for gene delivery 
possess useful inherent attributes, including a diameter of approximately 100 nm or less, a 
high drug-to-lipid ratio (in the case of lipid based systems), excellent retention of the 
encapsulated drug, and a long (> 6 h) circulation lifetime. These properties permit 
nanoparticles to protect their contents during circulation, prevent contact with healthy 
normal tissues, and accumulate at sites of disease. 
3.1 Viral and non-viral delivery systems 
A major impediment to the successful application of gene therapy for the treatment of a 
range of diseases is not a paucity of therapeutic genes, but the lack of an efficient non-toxic 
gene delivery system. Gene delivery is generally accomplished using one of two categories 
of delivery vector: 1) Viral delivery vectors derived from engineered retrovirus, adenovirus, 
herpesvirus, lentivirus or hybrid retro/adeno virus), and 2) Non-viral (synthetic) vectors 
comprised of polymers and lipids, naked DNA, plasmid-protein conjugates.  Other 
(physical as opposed to chemical) methods include microneedle coating, gene gun, and 
ultrasound/microbubble-mediated gene delivery.  
Viral vectors account for nearly 75% of all clinical trials conducted thus far 
(http://www.wiley.co.uk/genetherapy/ clinical). These vectors are essentially viruses 
that have been genetically modified to remove any replication/pathogenic genes, and 
instead encode a gene of interest (Hesdorffer et al. 1998).  This strategy preserves the 
viruses highly efficient ability to infect cells, while eliminating/attenuating toxicity. The 
most commonly used viral vectors are retroviral, adenoviral, adeno-associated viral and 
herpes simplex viral-based (Young et al. 2006). Although Vitravene, an antisense 
oligonucleotide-based product, is the only gene delivery product approved so far by US-
FDA, there are several other products in late stages of clinical trials. Gendicine, an 
adenovirus encoding the p53 gene, developed by SiBiono GeneTech Co., Ltd., was 
recently approved by China’s state Food and Drug Administration, for the treatment of 
head and neck squamous cell carcinoma. Virus-based treatments tend to maximize 
efficiency of gene transfer, often at the cost of safety, while non-viral options generally 
capitalize on a higher safety profile, but usually at the expense of Gene of Interest (GOI) 
expression efficiency. Many viruses including retroviruses, adenoviruses, herpes simplex 
viruses, adeno-associated viruses (AAV) and pox viruses have been modified to eliminate 
their toxicity, maintain their high gene transfer capability and long term gene expression. 
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However, despite these advantages, there are currently major limitations to the use of 
viruses as gene delivery vectors. These include the limited carrying capacity of transgenic 
materials (i.e. size of plasmid) since the packaging capacity of viral vectors (usually up to 
5 kb) is constrained; the potential for oncogenesis due to chromosomal integration or 
activation of oncogenes/inactivation of oncogene regulators; the generation of infectious 
viruses due to recombination; and concerns regarding instability that challenge 
production and storage.  
The potentially hazardous nature of viral vectors has been observed in a number of gene 
therapy-related patient mortalities in various clinical trials. Patient complications to date 
have included the rejection of DNA carriers, resulting in immune response that have led 
to already one death, Jesse Gelsinger, who died in 1999 from a rare metabolic disorder 
during a gene-therapy clinical trial at the University of Pennsylvania (Branca 
2005;Ledford 2007;Stolberg 1999;Wilson 2010). DNA constructs need to be optimized to 
carry minimal immunogenic components without compromising both efficient and long-
term transgene expression. In this context, technology employing minimal immunological 
defined gene expression technology (MIDGE) represents a promising future alternative to 
conventional plasmids in terms of biosafety, improved gene transfer, potential 
bioavailability, minimal size and low immunogenicity associated with these chemically 
engineered miniDNA vectors. MIDGEs are non-viral, lcc (linear covalently closed) 
miniplasmids synthesized in vitro via a patented chemical modification of linear open (lo). 
These plasmids confer the advantage of a minimal coding sequence that relieves 
complications from expression of additional unwanted genes and CpG motifs that have a 
20-fold higher occurrence in bacterial cells. MIDGE lcc plasmid transfection expression 
was reported to increase luciferase transgene expression from 2.5 to 17 fold ex vivo 
compared to circular covalently closed (ccc), isogenic forms in a tissue-dependent manner 
(Schakowski et al. 2007) . In addition, the mean numbers of MIDGE vector molecules per 
cell was also found to be significantly higher, suggesting that linear lcc plasmids transfect 
cells more efficiently. MIDGE technology has already been applied, with promising 
results, to the development of a Leishmania DNA vaccine and a colon carcinoma 
treatment. Here, therapy was based on IL-2 delivery to specific tumor cell lines ex vivo, 
and revealed 2 to 4 fold higher relative transgene expression compared to the ccc control 
(Schakowski et al. 2001). In combination, the existing studies employing lcc DNA systems 
suggest that lcc DNA is superior to lo DNA in transfection efficiency, and to ccc DNA in 
transgene expression. Purified TelN (closely related to Tel) was previously reported to 
generate lcc plasmids in vitro in (pal-related) telRL-dependent manner and was shown to 
successfully deliver EGFP to human embryonal kidney cells in vitro, as well as IL-12 in an 
untargeted manner to inhibit metastasis formation in B16F10C57BL/6 melanoma model 
mice in vivo (Heinrich et al. 2002). 
At present, our laboratory is involved in design, and construction of  bacteriophage-
encoded recombination systems  to generate linear covalently closed (lcc) DNA mini-
vectors. Conditional expression recombinase systems in vivo in E. coli provide a one step 
production system for step minivectors from specialized parental plasmids. The 
exploitation of this recombination system allows us to generate lcc miniplasmids that 
should have a preferential safety profile, preventing viable vector-chromosome, single 
recombination products in mammalian cells. In theory, the integration of covalently 
closed linear exogenous DNA into double-stranded (ds) DNA breaks is unlikely due to 
the unavailability of terminal ends, and a vector single recombination event into a target 
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chromosome should theoretically result in the disruption of the chromosome, killing the 
cell (see Figure 1).   
 
 
Fig. 1. Plasmid Integration Events: A miniplasmid that undergoes a single recombination 
event with the host chromosome should be rare due to the removal of all elements except 
the gene of interest. Any integration events by: A. A lcc miniplasmid should result in 
chromosomal disruption that is likely lethal and cannot be replicated or segregated; B. A ccc 
miniplasmid can integrate without disrupting the host chromosome. 
Non-viral gene delivery is emerging as a realistic alternative to the use of viral vectors with 
the potential to have a significant impact on clinical therapies. Synthetic vectors provide 
flexibility in formulation design and can be tailored to the size and topology of the DNA 
cargo and the specific route of vector administration, and can be delivered selectively to a 
specific tissue type through the incorporation of a targeting ligand. Compared to viral 
vectors, synthetic vectors are potentially less immunogenic, relatively easy to produce in 
clinically relevant quantities, and are associated with fewer safety concerns (Liu and Huang 
2002). As a result of these advantages, their use has rapidly moved from transfection of cell 
cultures to clinical cancer gene therapy applications.  
Synthetic vectors designed for parenteral administration encompass a wide range of 
formulations. These include unmodified (naked) DNA, which is designed for direct intra-
tissue injection, cationic polymer–DNA complexes, cationic lipid–DNA complexes, and 
cationic polymer–lipid–DNA ternary complexes (lipopolyplexes), which are mostly aimed at 
systemic administration. 
3.1.1 Naked DNA  
The simplest employed method of transgene delivery is the injection of naked DNA. It 
shows very little dissemination and transfection at distant sites following delivery and 
can be re-administered multiple times into mammals (including primates) without 
inducing an antibody response against itself (i.e., no anti-DNA antibodies generated) 
(Wolff and Budker, 2005). The simplicity of this approach is offset by serious limitations 
such as inefficient uptake of the therapeutic gene into the target cells and rapid clearance 
of the DNA from the circulation.  Direct in vivo gene transfer with naked DNA was first 
demonstrated by efficient transfection of myofibers following injection of mRNA or 
pDNA into skeletal muscle (Wolff JA, 1990). This novel approach was heralded as a 
superior method of in vivo transfection and its application was later advanced to confer 
high level expression in hepatocytes in mice by the rapid injection of naked DNA in large 
volumes into the tail vein (Zhang et al., 1999). This hydrodynamic tail vein (HTV) 
procedure has proven very useful not only to gene expression studies, but also more 
recently for the delivery of siRNA (Lewis et al., 2002; McCaffrey et al., 2002).  Ultrasound-
mediated eruption of polyethyleneglycol (PEG)-modified liposomes loaded with naked 
plasmid-DNA is also a feasible and efficient technique for gene delivery (Negishi et  
al. 2010).  
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3.1.2 Cationic liposomes  
Cationic liposomes are one of the most efficient, and among the most widely used non-viral 
vector systems. They are composed of positively charged lipid bilayers that can be complexed 
to DNA through electrostatic interactions resulting in complexes, termed lipoplexes. The 
application of cationic liposomes to gene therapy was first described in 1987 by Felgner 
(Felgner et al. 1987). The lipoplexes are generally composed of a positively charged lipidic 
component (see Figure 2), such as dioleylpropyltrimethylammonium chloride, dioleoyl 
triethylammonium propane (DOTAP), or dimethylaminoethane carbamoyl cholesterol (DC-
Chol), that is capable of complexing and condensing the DNA (Giatrellis et al. 2009). Most 
lipoplex formulations include a ‘‘helper’’ lipid, such as dioleoylphosphatidyl-ethanolamine 
(DOPE, as seen in Figure 2), or cholesterol that provides added stability to the lipoplexes and 
enhances DNA release from endosomal compartments. While transfection activity of 
lipoplexes is shown to vary depending on their DNA/cationic lipid ratio, it is necessary for 
them to be positively charged to interact with the negatively charge cell membranes and 
exhibit transfection activity. Lipoplex uptake occurs through endosome formation (via a 
number of mechnisms including caveosomes, clathrin dependent, etc.), followed by disruption 
of the endosomal membrane by fusion with, or incorporation of the lipoplex lipids resulting in 
DNA release.   
The advantages of liposomes in delivery system designs include their simplicity in 
preparation, ability to complex relatively large amounts of DNA, versatility for use with any 
size or type of DNA/RNA, ability to transfect non-dividing cells and overall stability (Dutta 
et al. 2010). In addition, lipids are non-immunogenic allowing for repeated administration 
without adverse immunologic reaction(Barron et al. 1999). The primary disadvantages of 
lipoplex delivery vectors include low tumor transfection efficiency and lack of tumor 
specificity.  
In order to enhance gene transfection, based upon structure-activity relationship, various 
gemini surfactants (Gemini surfactants consist of two hydrophobic chains and two polar 
headgroups linked chemically by a spacer group) have been designed. In order to enhance 
gene transfection based upon structure-activity relationship, various gemini surfactants 
have been designed, synthesized and tested for gene delivery in our  laboratory (Donkuru et 
al. 2010;Wang and Wettig 2011;Wettig et al. 2007a;Wettig et al. 2007b;Wettig and Verrall 
2001). Recent reports have shown that obstacles can be overcome by exploiting receptor-
mediated endocytosis for highly efficient internalization of ligands naturally employed by 
eukaryotic cells. Advances along this line include the conjugation of mAbs 
(“immunoliposomes”), ligands such as growth factors, or hormones to liposomes to confer 
targeting capability. Nanoparticle based anti-cancer gene/drug delivery first reached 
clinical trial in mid 1980s and the first nanomedicine Doxil® (liposomal encapsulated 
doxorubicin) was marketed in 1995. Other example of liposome-mediated drug delivery 
include daunorubicin (Daunoxome), which is also currently being marketed as liposome 
delivery systems. Numerous new nanoparticle based cancer gene therapy systems are under 
development. 
3.1.3 Polyplexes 
Polyplexes differ from lipoplexes in that they are comprised of charged complexes  
of plasmid DNA and a cationic polymer, such as poly-L-lysine (PLL), polyethylenimine, 
polyamidoamine (starburst) dendrimers, and chitosan with a net positive charge (See  
Figure 2). Cationic polymers differ from cationic lipids primarily in that they do not contain 
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a hydrophobic moiety and are completely soluble in water. A wide variety of cationic 
polymers that transfect cells in vitro have been characterized (Midoux et al., 2008). A key 
determinant of polyplex gene transfer efficiency is the positive (on amine nitrogen atoms in 
the polymer) to negative charge ratio or the related negative to positive (N/P) ratio. Given 
their polymeric nature, cationic polymers can be synthesized in different lengths, with 
different geometry (linear versus branched), and with substitutions or additions of 
functional groups with relative ease and flexibility, which opens the way to extensive 
















































Fig. 2. Examples of commonly used lipids (DOPE and DOTAP) and polymers (PEI and poly-
L-lysine) in gene therapy. 
Polymer-based nanoparticles are now widely used for gene and drug delivery and 
targeted therapy. One of the most widely applied cationic polymers used for DNA 
transfections is polyethyleneimine (Choosakoonkriang et al. 2003).  DNA complexation 
with PEI, has not been found to result in an alteration of DNA conformation, remaining 
essentially in the B form, and the utility of PEI as a gene delivery vector has been 
demonstrated in numerous studies (Jere et al. 2009;Moore et al. 2009).  High molecular 
weight PEI has been shown to be one of the most successful polymeric vectors due to the 
large number of protonatable amine groups that result in an enhanced ability to escape 
from the endosome following uptake by the cell via the so-called “proton sponge” effect. 
This benefit is contrasted by the high level of cellular toxicity also imparted by the 
number of amine groups within the polymer. Attempts to overcome this increased level of 
toxicity have involved using low molecular weight PEI; however, transfection efficiencies 
are directly correlated with decreases in molecular weight while the tendency to 
aggregate can increase with decreasing polymer molecular weight.  Another successful 
strategy has involved the shielding of the polyethylenimine/DNA core with a shell of 
polyethylene glycol (PEG). This approach results in the formation of a dense hydrophilic 
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outer surface of the complexes, reducing hydrophobic interactions with serum proteins 
and components of the reticulo-endothelial system (RES).  In addition to decreasing 
toxicity of the polyplexes, this strategy also confers increased biocirculation times and 
therefore, further increases transfection efficiencies. [Please see van Vlerken et al. 2007 for 
a recent review of PEG modification of nanocarriers].  The presence of the terminal 
alcohol groups in this PEG outer shell also provides sites for further modification that 
have been conjugated to various types of targeting ligands, including glycoprotein, 
transferring, carbohydrates, folate and epidermal growth factors, facilitating tissue-
specific gene delivery  (Guo and Lee 1999;Han et al. 1999;Lai et al. 2009). Such complexes 
have been found to mediate efficient gene transfer into tumor cell lines in a receptor-
dependent and cell-cycle-dependent manner. While the modifications described here have 
resulted in significant improvements in both the transfection efficiencies and toxicity 
profiles of polycation-based transfection vectors, a number of questions relating to 
mechanisms of endosome escape (Tros, I et al. 2010), structure-activitiy relationships, 
pharmacokinetics, and in-vitro vs in-vivo application remain (Jere et al. 2009). Overall, 
while proving to be a very promising strategy toward gene therapy design, polyplex 
systems still require much further testing and improvement prior to entering clinical trials 
(Midoux et al., 2008). 
3.1.4 Lipopolyplexes  
Lipopolyplexes (lipid-polymer-DNA complexes or LPDs) combine plasmid DNA with both 
a cationic polymer and liposomes via electrostatic interactions. In general, these vectors are 
compact particles that exhibit superior colloidal stability, reduced cytotoxicity, and provide 
elevated transfection efficiency compared to either polyplexes or lipoplexes alone. The 
cationic polymer may be covalently linked to the liposomes (e.g. lipopolylysine) or be non-
covalently incorporated into a ternary lipid–polymer–DNA complex  by a charge-mediated 
self-assembly process. The polycation component facilitates the optimal condensation of 
plasmid DNA, whereas lipidic components, to which targeting ligands can be attached, 
further stabilize the vector formulation and mediate the efficient endosomal escape of the 
vector following cellular internalization. LPD particles prepared using protamine as the 
cationic polymer and DOTAP/Chol cationic liposomes have been reported to inhibit tumor 
growth following i.v. administration in mice (Whitmore et al. 1999). Both in vitro and in vivo 
studies have demonstrated improved outcomes of (liposomes/protamine/DNA) LPD-
mediated gene transfer over conventional liposomes (El-Aneed 2004) .  It is believed that the 
small size of LPD (100 to 250 nm, which is almost three to five times less than conventional 
lipoplexes) will facilitate endocytosis and increase the in vivo circulating half life. 
4. Challenges in nanoparticle based gene therapy 
To facilitate efficient gene expression, delivered plasmid DNA must initially 
circumnavigate various barriers to cellular and nuclear entry as seen in Figure 3. The 
lipoplex/polyplex must first be internalized by the cell membrane,for which there are 
many different possible routes including receptor mediated endocytosis, pinocytosis and 
phagocytosis (Godbey and Mikos 2001). Receptor-mediated endocytosis or clathrin-
dependent internalization is the most common of these and can be exploited to engineer 
polyplexes to express attached ligands to facilitate this process (Morille et al. 2008). 
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Pinocytosis is the process by which cells internalize liquids which contain suspended or 
soluble particles. Untargeted polyplexes that interact with the cell membrane 
electrostatically may be internalized via this pathway .  Phagocytosis is another possible 
method of internalization involving the ingestion of larger particles greater than 0.5 μm in 
diameter.  
Targeting and internalization of microspheres to phagocytic cells in vivo can be achieved 
through size exclusion.  It is important to note that internalization mechanisms may also 
be largely dependent on the cell type, the vector used, and the process parameters of that 
a particular vector system (Duncan et al. 2006). On the cellular level, many complexes 
become buried in the endolysosomal compartment or are degraded in the cytoplasm. 
After internalization occurs, the lipoplex/polyplex is believed to be most commonly 
contained within an endocytic vesicle after which it is transferred to late endosomes and 
lysosomes. In these compartments the pH rapidly changes to the range of 4.5–6, and in 
order for successful transfection to occur the DNA must find a way to escape from these 
structures and reach the nucleus as DNA that remains in these cellular compartments is 
readily degraded (Pack et al. 2005). The final obstacle in the DNA vector’s journey is the 
double bilayer membrane surrounding the nucleus, or nuclear membrane. While small 
molecules may gain access to the nucleus directly through its network of pores, larger 
molecules must be internalized by specific nuclear import proteins. This process is largely 
dependent on the size of the DNA and its conformation. As such, in the absence of 
specialized enhancer sequences, nuclear import of plasmids is limited to actively dividing 
cells undergoing mitosis.  
In gene therapy studies, nuclear localization signal (NLS) peptides have been investigated as 
facilitators of nuclear transport with the aim of enhancing transgene expression. In order to 
improve overall transfection specificity and efficiency it is necessary to optimize 
intracellular trafficking of the DNA complex as well as the performance after systemic 
administration (Schatzlein 2001). Properties of vector such as size, shape, and surface 
characteristics can also have a major impact on its pharmacokinetic properties and delivery 
efficiency. For most nanoparticles, it is unknown what size and/or charge of nanoparticles 
could lead to defects in DNA transcription and chromosomal damage and aberration. 
However, there are indications that certain types of nanoparticles are capable of causing 
DNA damage, where the composition and the coating of nanoparticles are likely the key 
factors imparting genotoxic effects.  
With respect to systematic in vivo applications, nanocarrier approaches face additional 
hurdles. First, despite advances in using PEG or other hydrophilic polymers for extracellular 
stability to prolong their circulation in the blood stream, a large fraction of the injected dose 
of nanoparticles accumulates in the liver and is taken up by hepatic phagocytes.  Second, 
due to the vascular endothelial barrier, nanoparticles can only reach certain tissues such as 
the liver, spleen, and some types of tumors as a result of enhanced permeability and 
retention (an effect due to the presence of fenestrated endothelium in tumor blood vessels i.e 
passive targeting) effect, where the nanoparticles tend to accumulate in tumor tissues much 
more than in normal tissues. However, nanoparticles cannot, or rarely access, parenchymal 
cells in most normal tissues as they are simply excluded by the endothelial barrier. Thus, 
many potential disease targets cannot at present be addressed by existing nanocarrier 
approaches.  
www.intechopen.com






Fig. 3. A schematic generalized diagram of folate receptor/ non-receptor mediated non-viral 
delivery system: The tethers connecting the folate to the lipid headgroups consist of 250 Å 
long polyethyleneglycol spacers. Condensation/ complexation of DNA-based therapeutics 
with DNA delivery vector; (B, C) Non-specific adsorption to cell membrane and cellular 
internalization via non-receptor mediated (passive entry) or folate-receptor (folate tittered 
PEGylated liposome’s shown in yellow balls and encapsulated drugs as red stars) mediated 
endocytosis pathway; (D) Monoclonal antibody-antigen complex mediated endocytosis 
pathway; (E) Uptake and degradation via endosome. lysosome; (F) Low pH dependent 
destabilization of endosome membrane; (G) Cytoplasmic release of plasmid DNA and drug 
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4.1 Targeted nanomedicine  
Construction of organ-targeted gene delivery vectors is a promising route to improve the 
safety and efficacy of nanomedicine based cancer gene therapy. There are a variety of 
‘vector targeting’ strategies, that can be accomplished using transcriptional targeting, 
transductional targeting, or ideally, a combination of these. While transcriptional targeting 
refers to the use of gene regulatory elements (promoters and enhancers) to restrict gene 
expression to specific cells, transductional targeting refers to the delivery of DNA to specific 
cells. Targeted gene expression has been analyzed using tissue-specific promoters (breast-, 
prostate-, and melanoma-specific promoters) and disease-specific promoters 
(carcinoembryonic antigen, HER-2/neu, Myc-Max response elements, DF3/MUC).  
The addition of a ligand (i.e., folate, transferrin, RGD peptide, among others) to the 
nanoparticle surface, thus targeting the DNA to cells in vivo has been demonstrated quite 
successfully. Folate-receptor-targeted liposomes have proven effective in delivering 
doxorubicin in vivo and have been found to bypass multidrug resistance in cultured tumor 
cells (Immordino et al. 2006). Hong et al., (2010) exploited the possibility of combination of 
the functions of passive and active targeting by transferring-PEGlyated nanoparticles  
(Tf-PEG-NP), as well as sustained drug release in tumor by PEGylated drug for most 
efficient tumor targeting and anti-tumor effects enhancement. Such Tf-PEG-NP loaded with 
PEGylated drug conjugates could be one of the promising strategies in nanomedicine to 
deliver anti-tumor drugs to tumor (Hong et al. 2010). Further enhancement of the 
therapeutic index may also be achieved by overcoming barriers both at cellular and nuclear 
levels. In gene therapy studies, nuclear localization signal peptides have been investigated 
as facilitators of nuclear transport with the aim of enhancing transgene expression. Selective 
tumor targeting with minimal toxicity using folate modified, incorporating nuclear 
localization signal represents a popular approach. In recent years, Poly(ε-
caprolactone)/poly(ethylene glycol) (PCL/PEG) copolymers which are biodegradable and 
amphiphilic, are also emerging as a potential nanoplatform for anticancer agent delivery 
(Gou et al. 2011). 
5. Nanobased cancer diagnosis approaches 
Current problems and unmet needs in translational oncology include (i) advanced 
technologies for tumor imaging and early detection, (ii) new methods for accurate diagnosis 
and prognosis, (iii) strategies to overcome the toxicity and adverse side effects of 
chemotherapy drugs, and (iv) basic discovery in cancer biology leading to new knowledge 
for treating aggressive and lethal cancer phenotypes such as bone metastasis. Advances in 
these areas will undoubtedly form the major cornerstones for a future medical practice of 
personalized oncology. Cancer detection, diagnosis, and therapy will be tailored to each 
individual's tumor molecular profile and used in predictive oncology, whereby 
genetic/molecular markers will play an essential role in the prediction of disease 
development, progression, and clinical outcomes.  
The probability of a successful treatment modality increases dramatically if tumor cells can 
be selectively removed before they evolve to their mature stages and metastases production. 
As such, novel and more sensitive diagnostic tools like metallic and semiconducting 
nanoparticles are being developed with the aim of improving the early and noninvasive 
detection of rising malignancies and the accuracy of tumor tissue localization. Paramagnetic 
nanoparticles, quantum dots, nanoshells and nanosomes represent some of these new 
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technologies, used for diagnostic purposes (See Figure 4). Compared to conventional 
materials, inorganic nanomaterials provide several advantages such as simple preparative 
processes and precise control over their shape, composition and size. These systems provide 
promising potential not only in diagnostics, but also as delivery systems for therapeutic 






















Fig. 4. Nanoparticles used in cancer diagnosis and treatment. Liposomes contain 
amphiphilic molecules, which have hydrophobic and hydrophilic groups that self-assemble 
in water. Gold nanoparticles are solid metal particles that are conventionally coated with 
drug molecules, proteins, or oligonucleotides. Quantum dots consist of a core-and-shell 
structure (e.g., CdSe coated with zinc and sulfide with a stabilizing molecule and a polymer 
layer coated with a protein). Fullerenes (typically called “buckyballs” because they resemble 
Buckminster Fuller's geodesic dome) and carbon nanotubes have only carbon-to-carbon 
bonds.  
5.1 Quantum dots 
Quantum Dots (QDs) are a unique class of light emitting semiconductor nanoparticles ranging 
from 2-10 nanometers in diameter and are becoming highly popular for biological imaging 
due to their high intensity and stable fluorescence profile (most QDs are approximately 10–20× 
brighter than organic dyes). QDs usually consist of a CdSe core surrounded by a inorganic 
shell composed of ZnS (Pinaud et al. 2010). For biological imaging applications, they are given 
hydrophilic coatings of PEG or multiple carboxylate groups.  
A. Nanoparticles in proof of concept/ research stages
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Compared to the commercially available organic dyes and fluorescent proteins used in 
medical imaging, QDs provide many advantages (Park et al. 2009;Pic et al. 2010;Rogach and 
Ogris 2010;Yong et al. 2009). The first and foremost important feature is the long-term 
photostability of QD imaging probes, which opens the possibility of investigating the 
dynamics of cellular processes over time, such as continuously tracking cell migration, 
differentiation, and metastasis. In addition, QD emission wavelengths are size-tunable and 
extend from visible to near infrared (NIR) (650 nm to 950 nm), to take advantage of the 
improved tissue penetration depth and reduced background fluorescence at these 
wavelengths. For example, CdSe/ZnS QDs of approximately 2 nm in diameter produce a 
blue emission, while QDs approximately 7 nm in diameter emit red light. While 
fluorescence imaging is often limited by the poor transmission of visible light through 
biological tissue, there is a NIR optical window in most biological tissue that is suitable for 
deep tissue optical imaging, where only a few organic dyes emit brightly in this region and 
generally suffer from photobleaching. In contrast, the novel optical properties of QDs allow 
the synthesis of bright and stable fluorescent labels that emit in the near infra red spectrum 
by adjusting their size and composition.  
Surface functionalization using peptides, proteins and antibodies, confers the ability of QDs 
to provide high biological compatibility and capacity to target and image tumors in living 
subjects through the rapid readout of fluorescence imaging. Moreover, QDs allow imaging 
of deeper tissues and is also used to image lymph nodes and blood vessels in tissues. A key 
property for in vivo imaging is the unusual QD Stokes shift (measured by the distance 
between excitation and emission peaks), which can be as large as 300-400nm depending on 
the wavelength of the excitation light, which can be used to further improve the detection 
sensitivity. Organic dye signals with a small stoke shift are often buried by strong tissue 
autofluorescene, whereas QD signal with large Stokes shift are clearly detectable above 
the background. Unlike traditional dyes which usually show a broad emission band, QDs 
exhibit narrow sharp emission peaks and broadband absorption, which are ideal for 
multiplexed multicolor imaging. QDs are thus able to increase the number of labels that 
can be used simultaneously in a single system. The effective brightness per probe particle 
is also superior with quantum dots as evidenced by their large molar absorption cross-
sections which are a consequence of their nanometer size and composition. Different from 
“soft” organic nanoparticles (e.g., polymers, micelles, liposomes), inorganic nanomaterials 
with rigid cores usually show inefficient extravasation inside tumors. A number of reports 
suggest that QDs tend to stay within the tumor vasculatures without getting into the 
interstitial space or tumor cells, reducing the nonspecific tumor cell labeling in 
angiogenesis imaging (Liu and Peng 2010). The long term photostability and superior 
brightness of QDs make them appealing for live animal targeting and imaging. These 
properties have made QDs a topic of intensive interest in cancer biology, molecular 
imaging, and molecular profiling.  
The ability to functionalize as well as control the surface of quantum dots with specific 
linkers and multi-functional molecules is critical for nanoparticle-based gene therapy. 
Currently, QDs are used both as a transfection vector as well as a fluorescence label in RNA 
interference research. Quantum dot conjugates have been successfully used for targeted 
silencing of bcr/abl gene by RNA interference in human myelogenous leukemia K562 cells 
(Zhao et al. 2010). In addition, Derfus et al., (2007) using PEGlyated quantum dot core as a 
scaffold, and conjugating siRNA and tumor-homing peptides (F3) to functional groups on 
the particle's surface found that the homing peptide was required for targeting 
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internalization by tumor cells, and that siRNA cargo could be co-attached without affecting 
the function of the peptide (Derfus et al. 2007). Using an EGFP model system, the role of 
conjugation chemistry was also investigated, with siRNA attached to the particle by 
disulfide cross-linkers showing greater silencing efficiency than when attached by a non-
reducible thioether linkage. Delivery of these F3/siRNA-QDs to EGFP-transfected HeLa 
cells and release from their endosomal entrapment led to significant knockdown of EGFP 
signal. By designing the siRNA sequence against a therapeutic target (e.g., oncogene) 
instead of EGFP, this technology may be ultimately adapted to simultaneously treat and 
image metastatic cancer. These nanoprobes could be used for both active and passive 
targeting. Therefore, in future research, QDs can be seen as multi-functional platforms 
focusing on targeted delivery, high transfection efficiency, and multi-modal 
imaging/tracking and treatment of cancer as shown in Figure 5. 
  
 
Fig. 5. (A): Quantum dots as a multi-functional nanoplatform to deliver siRNA and to 
elucidate of EGFR knockdown effect of PI3K signaling pathway in brain tumor cells. (B): 
Detailed structural information of multifunctional siRNA-QDs: CdSe as core with ZnS 
capping along with thiol reactive linker for siRNA conjugation as well as RGD peptides as 
shown in red and TAT peptides as shown in green. In order to make QD constructs water-
soluble and suitable for conjugating with siRNA, hydrophobic ligands are displaced  
with a dihydrolipoic acid (DHLA) derivatized with an amine terminated polyethylene 
glycol (PEG) spacer. (C): Two different strategies for the siRNA-QD conjugate. (C1)  
Linker for attaching siRNA to QDs through a disulfide linkage which are easily reduced 
within the cells to release the siRNA. (C2) Linker for covalently conjugating siRNA to  
QDs which enable tracking of siRNA-QDs within the cells. (Taken from:  
Jung et al. 2010). 
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However, there have been some QD concentration dependent toxicity and distribution 
concerns. QDs have been shown to remain in liver, lymph nodes and bone marrow  
of mice for 1 month after tail injection, despite of its low affinity to cells and tissues 
(Ballou et al. 2004;Ballou et al. 2009). Recently, the hydrophilic QDs (diameter <10 nm) 
have attracted more attention for in vivo applications, due to the rapid renal clearance of 
QDs, minimizing the potential toxicity to the system (Park et al. 2009). Recently, Peng and 
co-workers developed InAs/InP/ZnSe core/shell/shell QDs with high quantum yield 
(76%) of NIR fluorescence, ultrasmall hydrodynamic sizes (< 10 nm), and the 
biocompatibility desired for in vivo applications (Liu and Peng 2010). These novel QDs 
have obviously lower intrinsic toxicity compared to commercial Cd-containing NIR 
emitting QDs and showed significantly improved circulation half-life with reduced RES 
uptake. NIR-emitting QDs demonstrate exceptional brightness and fluorescent quantum 
yields. Also, once capped with a chemically stable shell, QDs can exhibit remarkable 
photostability, providing continuous fluorescent singles for long-term imaging 
applications. Other types of novel QDs with entirely different compositions and 
photoluminescence mechanism such as silicon QDs and carbon dots have also emerged as 
potential probes in bioimaging applications. Further, typical fluorescence images of  
a single QD shows changes in emission intensity. The intensity time trace illustrates  
the random alternation between “on” and “off” states, which is known as blinking and  
it is a signature feature of an individual QD. Also, reducing size of QDs has proven 
difficult because of decreased colloidal stability and increased nonspecific interactions. 
Other major limitations include reproducibility in production, proper control of surface 
functionality, bulky surface coatings (PEG, multiple antibodies, ampiphilic molecules) 
which leads to restrictions on studying spatially confined, crowded regions of the cell  
and may also perturb the behavior of the labeled molecules. Quantum dots are not  
yet approved for use in humans and much more research is needed in future for this 
growing field. 
5.2 Carbon nanotubes 
Molecular imaging exploits the specific recognition of labeled probes to their biological 
targets in conventional imaging techniques to monitor biological processes at the molecular 
level with improved specificity and sensitivity. Conventional clinical cancer imaging 
techniques, such as X-ray, CT and MRI, do not possess sufficient spatial resolution for early 
detection of the disease. Positron emission tomography (PET) is a highly sensitive and 
accurate imaging technology that relies on changes in tissue biochemistry and metabolism. 
It is the most valuable means we have so far to identify early-stage alterations in molecular 
biology, often before there is any morphologic change. Nevertheless, fluoro-desoxy-glucose 
(FDG), the most commonly used PET tracer in clinical oncology (more than 95% of the 
molecular imaging procedures make use of FDG at present), is not a specific tracer for 
malignant diseases but for increased metabolism. Therefore, it is imperative to develop new 
tools for early cancer diagnosis. 
CNTs have been explored in almost every single cancer treatment modality, including drug 
delivery, lymphatic targeted chemotherapy, thermal therapy, photodynamic therapy, and 
gene therapy. Based on their structure, CNTs can be classified into two general categories: 
single-walled (SWNTs), which consist of one layer of cylinder graphene (diameter 0.4-2 nm) 
and multi-walled (MWNTs), which contain several concentric graphene sheets (diameter 2-
100 nm). CNTs have unique physical and chemical properties such as high aspect ratio, 
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ultralight weight, high mechanical strength, high electrical conductivity, and high thermal 
conductivity (Ji et al. 2010). Carbon nanotubes are the strongest and stiffest materials yet 
discovered in terms of tensile strength and elastic modulus respectively. As CNTs are 
intrinsically not water soluble, modification through chemical functionalization can 
increases the solubility of carbon nanotubes in aqueous solutions.  
Imaging functionalities and therapeutics can be incorporated on the same nanoparticle for 
multifunctional cancer imaging and treatment. SWNT-paclitaxel (PTX) conjugates also 
showed higher efficacy in suppressing tumor growth than clinical Taxol alone in a murine 
4T1 breast cancer model, owing to prolonged blood circulation time and enhanced 
permeability and retention (EPR) in the tumor (Feazell et al. 2007). Besides, with very high 
surface area per unit weight, SWNTs provide higher capacity of drug loading, compared to 
that reported for conventional liposomes and dendrimer drug carriers. Doxorubicin, a 
commonly used cancer chemotherapy drug, can be loaded on the surface of PEGylated 
SWNTs with remarkably high loading, up to 4 g of drug per 1 g of nanotube, owing to the 
ultrahigh surface area of SWNTs. Further, the intrinsic stability and structural flexibility of 
CNTs may prolong the circulation time as well as improve the bioavailability of drug 
molecules conjugated to them. Surface-enhanced Raman spectroscopy of carbon nanotubes 
opens up a method of protein microarray with detection sensitivity down to 1 fmol/L. In 
vitro and in vivo toxicity studies reveal that highly water soluble and serum stable nanotubes 
are biocompatible, nontoxic, and potentially useful for biomedical applications. However, 
nonfunctionalized nanotubes are toxic to cells and animals and therefore one has to be 
cautious about the safety aspects of CNTs. If well functionalized, nanotubes may be excreted 
mainly through the biliary pathway in feces.  
Carbon nanotube-based drug delivery has shown promise in various in vitro and in vivo 
experiments including delivery of small interfering RNA (siRNA), paclitaxel and 
doxorubicin (Liu et al. 2009). Multiwalled PEGylated carbon nanotubes are found to be 
successful, effective and do not alter particle sizes and zeta potentials of carbon nanotubes 
after PEGylation (Ilbasmis-Tamer et al. 2010). In addition, the propensity to absorb the body 
transparent NIR radiation also envisages photothermal and photoacoustic therapy using 
nanotubes.    
5.3 Gold and other nanoparticles for cancer diagnosis 
Thermal ablation therapy is one the most promising of methods in cancer treatment but is 
limited by incomplete tumor destruction and damage to adjacent normal tissues. Current 
radiofrequency ablation techniques require invasive needle placement and are limited by 
accuracy of targeting. Use of nanoparticles has refined noninvasive thermal ablation of 
tumors, and several nanomaterials have been used for this purpose. These include gold 
nanomaterials, iron nanoparticles, magnetic nanoparticles, carbon nanotubes and affisomes 
(thermosensitive liposomes). Heating of the particles can be induced by magnets, lasers, 
ultrasound, photodynamic therapy and low-power X-rays. The clinical trials include studies 
of designed nanoparticles such as the thermosensitive liposomal doxorubicin (Thermodox®) 
as a novel activated therapy using radiofrequency ablation (Wang and Thanou 2010). As 
gold nanoparticles have evolved other gold structures have also been suggested. Nanorods, 
with the appropriate PEG stealth layer, are being developed as an improved means of 
hyperthermia. By attaching monoclonal antibodies (mAbs), which can recognize a specific 
cancer cell, to gold nanoparticles or nanorods are also used in cancer detection. Gold 
nanoparticles conjugated to anti-epidermal growth factor receptor (El-Sayed et al. 2006) 
www.intechopen.com
 Non-Viral Gene Therapy 
 
538 
mAbs specifically and homogeneously bind to the surface of the cancer cells with 600% 
greater affinity than to the noncancerous cells. This specific and homogeneous binding is 
found to give a relatively sharper surface plasma resonance (Hinz et al. 2006) absorption 
band with a red shifted maximum compared to that observed when added to the 
noncancerous cells . Surface plasma resonance scattering imaging or SPR absorption 
spectroscopy generated from antibody conjugated gold nanoparticles may be useful in 
molecular biosensor techniques for the diagnosis and investigation of cancer cells in vivo and 
in vitro.   
These inorganic nanoparticles represent a different class of nanoparticles that are usually 
much smaller, 5–40 nm and they do not have the flexibility observed in liposomes and 
polymeric nanoparticles. Inorganic nanoparticles have made their appearance in cancer 
therapy during the last decades in a number of applications. The main type of inorganic 
nanoparticles—the iron oxide nanoparticles, has been used for imaging tumor (Wang and 
Thanou 2010). The main advantage of magnetic nanoparticles is their ability to be 
visualised by Magnetic Resonance (MR) imaging. Additionally, iron oxide nanoparticles 
can be guided to target sites (i.e. tumor) using external magnetic field and they can be also 
heated to provide hypethermia for cancer therapy. Yu et al. reported thermally cross-
linked superparamagnetic iron oxide nanoparticles that could carry a Cy5.5 near infra-red 
probe (dual imaging) and doxorubicin for the imaging and treatment of cancer. The 
nanoparticles substantially diminished tumor size and provided the proof of concept that 
they can combine several modalities for maximum antitumor effect (Yu et al. 2010). 
Magnetic nanoparticles have been used in the development of dual purpose probes for the 
in vivo transfection of siRNA. The iron nanoparticles deliver siRNA at the same time as 
imaging their own accumulation in tumor sites. Hence, multifunctional nanoparticles 
have emerged that are capable of cancer targeting and simultaneous cancer imaging and 
therapy. 
Metal nanoshells are another class of nanoparticles with tunable optical resonances. Metal 
nanoshells consist of a spherical dielectric core nanoparticle, in this case silica, which is 
surrounded by a thin metal shell, such as gold. These particles possess a highly tunable 
plasmon resonance, a resonant phenomenon whereby light induces collective oscillations of 
conductive metal electrons at the nanoshell surface. Nanoshells derived from gold provide 
an attractive system for imaging applications owing to the established ease of preparation, 
chemical inertness, good biocompatibility, and surface functionalization. Further, 
nanoparticle based near infrared imaging (NIR) is steadily presenting itself as a powerful 
diagnostic technique with the real potential to serve as a minimally invasive, nonionizing 
method for sensitive, deep tissue diagnostic imaging that are not prone to the rapid 
photobleaching and instability of their organic counterparts. NIR  laser treatment of the bulk 
tissue selectively heats and destroys the nanoshell-laden tumor regions within the tissue, 
while leaving surrounding tissue intact. Nanoshells are currently evaluated in a number of 
clinical settings after a 5-year period of intensive preclinical development. Such 
development of nanoshells included the combination of nanoshells with cancer antibodies. 
Anti-HER2 antibody conjugated onto nanoshells provides the potential of combining 
antibody therapy with imaging and hyperthermia. NIR dye-encapsulating nanoparticles 
also demonstrate improved optical performances compared to unencapsulated organic 
fluorophores. Specifically, the encapsulation shields the dye molecules from unfavorable 
environmental influences that normally hinder fluorescence signals, thereby enhancing 
quantum yields, emission brightness, and fluorescent lifetime. While, at present, these NIR 
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nanoparticulates appear to be superior in terms of optical performances, they are marred by 
their heavy metal composition and high propensity for toxicity. It is therefore reasonable to 
be concerned about the ineffectual clearance and long-term accumulation in untargeted 
organs and tissues of these particulates for in vivo use. 
6. Conclusion 
With the understanding of the genetic origins of certain cancers, an entirely new approach 
to the treatment of this disease has evolved, employing nanoparticle-based gene therapy. 
Numerous nanoparticle based cancer gene therapy strategies are already in clinical trials. 
The key to the success of any new therapeutic is to maximize safety without compromising 
efficacy, which has led to growing interest in non-viral gene delivery systems (such as 
liposomes) over the viral gene delivery systems. Grafting biorecognition molecules (ligands, 
antibodies) onto the nanoparticles (i.e active targeting) aims to improve targeting by specific 
cell uptake and using hydrophilic polymer coating, PEG, which  aims to further enhance 
biocompatibility.  To overcome other challenges of gene therapy, such as escape from 
endosome and other nuclear and cytosolic barriers, next generation vectors are being 
designed with use of gene regulatory elements (promoters and enhancers) to restrict gene 
expression to specific cells, along with nuclear localization signal peptides for nuclear 
targeting.  
There has been substantial interest in dual purpose nanoparticle based gene therapy for 
both diagnostic (imaging) and therapeutic purposes (drug/gene delivery). Newer 
technologies for cancer detection/diagnosis using metallic and semiconducting 
nanoparticles are also under intense investigation. These nanoparticles for in vivo 
application targeting cancer are amenable to different size structures and possess tunable 
properties. Quantum dots possess unique size- and composition- dependent optical and 
electrical properties. In addition to quantum dots, carbon nanotubes, paramagnetic 
nanoparticles, nanoshells and nanosomes represent just a few of these novel technologies, 
used for both diagnostic and delivery purposes.  
The imminent research challenge facing investigators moving forward is the expansion of 
the knowledge and understanding of the chemical and physical properties associated with 
these nanoparticle systems toward the design of superior cancer therapy modalities that 
maximize efficiency of treatment, while maintaining a superior safety profile. 
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